Veraxa Biotech AG Warrants
VRXAW
Last
$0.04
Day
+16.7%
1y
-77.8%
5y
-65.4%
52w
-91.2%
SPY YTD
+13.3%
Sec
—
Earnings
—
EMA 21
0.07
EMA 50
0.10
EMA 200
0.15
20d high
-70.4%
5y high
-91.2%
5y range
0th
Positions held
Your positionsVRXAW isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-24
Hold
avoid
Signal
Strong Sell
Target
$0.05
Stop
$0.02
Stop distance
44.9%
Target vs last
+37.7%
Fundamentals
| Market cap | — | Enterprise value | — | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | -0.02 | Beta | 0.19 | Dividend yield | — |
| Revenue growth | — | Earnings growth | — | Gross margin | 66.0% | Operating margin | -2826.6% |
| Profit margin | 0.0% | ROE | -8.7% | ROA | -50.0% | Debt / equity | — |
| Current ratio | 0.44 | Free cash flow | $15.75M | Analyst recommendation | none | Mean target | — |
| 52w high | $0.04 | 52w low | $0.03 |
Quarterly
No data yet.
Yearly (6y)
No data yet.
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-04 · VERAXA Biotech Appoints Raju Willener as Chief Financial Officer
2026-08-28 · VERAXA Biotech (VRXA), Secarna Partnership Milestone Opens New Potential Market for Conjugation Technology
2026-08-24 · VERAXA Biotech (VRXA) Builds Antibody-Based Cancer Pipeline Around Dual-Targeting Precision
Price (daily)
Full chart · RSI · MACD · patternsVRXAW · daily-68.0% over 12 sessions
Close EMA21 EMA50 EMA200